Product Code Database
Example Keywords: the legend -dungeon $8
   » » Wiki: Esomeprazole
Tag Wiki 'Esomeprazole'.
Tag

Esomeprazole, sold under the brand name Nexium or among others, is a medication which reduces . It is used to treat gastroesophageal reflux disease, , and Zollinger–Ellison syndrome.

(2025). 9780857113382, Pharmaceutical Press.
Its effectiveness is similar to that of other proton pump inhibitors (PPIs). It is taken by mouth or .

Common side effects include headache, constipation, dry mouth, and abdominal pain. Serious side effects may include , Clostridioides difficile infection, and . Use in appears to be safe, while safety during is unclear. Esomeprazole is the ( S)-(−)- (or less specifically the S-) of . It works by blocking H+/K+-ATPase in the of the stomach.

It was patented in 1993 and approved for medical use in 2000.

(2025). 9783527607495, John Wiley & Sons. .
It is available as a generic medication and sold over the counter in several countries.
(2025). 9781284121346, Jones & Bartlett Learning. .
In 2022, it was the 122nd most commonly prescribed medication in the United States, with more than 5million prescriptions. In Australia, it was one of the top 10 most prescribed medications between 2017 and 2023. It is also available in lower dose formulations without a prescription in the United States, the United Kingdom as well as Australia, Canada, and New Zealand.


Medical use
The primary uses of esomeprazole are gastroesophageal reflux disease, treatment and maintenance of erosive esophagitis, treatment of caused by H. pylori, prevention of in those on chronic therapy, and treatment of gastrointestinal ulcers associated with Crohn's disease.


Gastroesophageal reflux disease
Gastroesophageal reflux disease (GERD) is a condition in which the digestive acid in the stomach comes in contact with the . The irritation caused by this disorder is known as . Long-term contact between gastric acids and the esophagus can cause permanent damage to the esophagus and is associated with Barrett's esophagus. Esomeprazole reduces the production of digestive acids, thus reducing their effect on the esophagus.


Duodenal ulcers
Esomeprazole is combined with the antibiotics and (or instead of amoxicillin in penicillin-hypersensitive patients) in a 10-day eradication triple therapy for Helicobacter pylori. Infection by H. pylori is a causative factor in the majority of .


Efficacy
A 2006 meta analysis concluded that compared to other proton pump inhibitors, esomeprazole confers a modest overall benefit in esophageal healing and symptom relief. When broken down by disease severity, the benefit of esomeprazole relative to other proton pump inhibitors was negligible in people with mild disease (number needed to treat 50), but appeared more in those with severe disease (number needed to treat 8). A second meta analysis also found increases in erosive esophageal healing (>95% healing rate) when compared to standardized doses in broadly selected patient populations. A 2017 study found esomeprazole to be among a number of effective PPIs.


Adverse effects
Common side effects include headache, , , , decreased appetite, , dry mouth, and abdominal pain. More severe side effects are severe allergic reactions, chest pain, dark urine, fast heartbeat, fever, , persistent sore throat, severe stomach pain, unusual bruising or bleeding, unusual tiredness, and yellowing of the eyes or skin.

Proton pump inhibitors may be associated with a greater risk of hip fractures and Clostridioides difficile-associated . Patients are frequently administered the drugs in intensive care as a protective measure against ulcers, but this use is also associated with a 30% increase in occurrence of .

Long-term use of proton pump inhibitors in patients treated for Helicobacter pylori has been shown to dramatically increase the risk of gastric cancer.

Acute tubulointerstitial nephritis is a possible adverse reaction when using proton pump inhibitors.


Interactions
Esomeprazole is a of the enzyme CYP2C19, and may therefore with drugs that depend on it for , such as and ; the concentrations of these drugs may increase if they are used concomitantly with esomeprazole. Conversely, (Plavix) is an inactive that partially depends on CYP2C19 for conversion to its active form; inhibition of CYP2C19 blocks the activation of clopidogrel, thus reducing its effects.

Drugs that depend on stomach pH for absorption may interact with esomeprazole; drugs that depend on an acidic environment (such as or ) will be poorly absorbed, whereas drugs that are broken down in acidic environments (such as ) will be absorbed to a greater extent than normal.


Pharmacokinetics
Single 20 to 40mg oral doses generally give rise to peak plasma esomeprazole concentrations of 0.5-1.0mg/L within 1–4 hours, but after several days of once-daily administration, these levels may increase by about 50%. A 30-minute intravenous infusion of a similar dose usually produces peak plasma levels on the order of 1–3mg/L. The drug is rapidly cleared from the body, largely by urinary excretion of pharmacologically inactive metabolites such as 5-hydroxymethylesomeprazole and 5-carboxyesomeprazole. Esomeprazole and its metabolites are analytically indistinguishable from omeprazole and the corresponding omeprazole metabolites unless chiral techniques are employed.
(2025). 9780962652370, Biomedical Publications.


Dosage forms
Esomeprazole is available as delayed-release capsules in the United States or as delayed-release tablets in Australia, the United Kingdom, and Canada (containing esomeprazole magnesium) in strengths of 20 and 40mg, as delayed-release capsules in the United States (containing esomeprazole strontium) in a 49.3mg strength (delivering the equivalent of 40mg of esomeprazole, and as esomeprazole sodium for injection/infusion. Oral esomeprazole preparations are , due to the rapid degradation of the drug in the conditions of the . This is achieved by formulating capsules using the multiple-unit pellet system.

The combination naproxen/esomeprazole magnesium (brand name Vimovo) is used for the prevention of gastric ulcers associated with chronic therapy. Vimovo is available in two dosage strengths: 500/20mg and 375/20mg. Clinical trials of naproxen/esomeprazole demonstrated an incidence of GI ulcer in 24% of patients on naproxen (alone) versus 7% on naproxen/esomeprazole. The FDA has added warnings to the label for Vimovo concerning acute interstitial nephritis and risk of problems in some patients.


Multiple-unit pellet system
Esomeprazole capsules, as well as Losec/Prilosec tablets, are formulated as a "multiple-unit pellet system" (MUPS). Essentially, the capsule consists of extremely small enteric-coated granules (pellets) of the esomeprazole formulation inside an outer shell. When the capsule is immersed in an aqueous solution, as happens when the capsule reaches the stomach, water enters the capsule by . The contents swell from water absorption, causing the shell to burst, and releasing the enteric-coated granules. For most patients, the multiple-unit pellet system is of no advantage over conventional enteric-coated preparations. Patients for whom the formulation is of benefit include those requiring feeding and those with difficulty swallowing ().


Society and culture

Global distribution
In 2010, AstraZeneca announced a co-promotion agreement with to distribute Nexium in Japan. In September 2011, Nexium was approved for sale and was launched by Daiichi Sankyo in Japan. Esomeprazole was approved for use in the United States in February 2001.


Economics
Between the launch of esomeprazole in 2001 and 2005, the drug netted AstraZeneca about $14.4billion.Financial impact information:
  • ;
  • ;
  • ;
  • ;


Controversy
There has been some controversy about 's behaviour in creating, patenting, and marketing the drug. Esomeprazole's successful predecessor, , is a mixture of two mirror-imaged molecules (esomeprazole which is the S-enantiomer, and R-omeprazole); critics said the company was trying to "" its omeprazole patent by patenting the pure esomeprazole and aggressively marketing to doctors that it is more effective than the mixture.


Brand names
Generic versions of esomeprazole magnesium are available worldwide. It is available under the brand name Nexium in the United States and the UK.


Veterinary use
Injection formulations of esomeprazole are used for gastroprotection in veterinary medicine. In goats administered the drug by intravenous or subcutaneous injection rapid elimination was noted. In that study the sulfone metabolite was detectable for several hours after injection of the parent drug.


Other uses
Esomeprazole can be used as a . Gokmen et al., 2016 screen for efficacy against Trichomonas vaginalis isolates from . They found esomeprazole to be effective as a veterinary antiparasitic.
(2025). 9780128138908, .


Further reading
Page 1 of 1
1
Page 1 of 1
1

Account

Social:
Pages:  ..   .. 
Items:  .. 

Navigation

General: Atom Feed Atom Feed  .. 
Help:  ..   .. 
Category:  ..   .. 
Media:  ..   .. 
Posts:  ..   ..   .. 

Statistics

Page:  .. 
Summary:  .. 
1 Tags
10/10 Page Rank
5 Page Refs
1s Time